RBC Capital cuts Brookfield Asset Management price target on valuation

RBC Capital cut its price target on Brookfield Asset Management to $65 from $74 but kept an Outperform rating, implying upside from the current $49.76 share price. The firm expects about $150 billion of fundraising in 2026, or $110 billion excluding the Just Group mandate, supported by private equity and infrastructure strategies. Brookfield has also repurchased $575 million of stock year-to-date and yields about 4%, while recent first-quarter 2026 results were described as strong.

Analysis

The key read-through is not the higher or lower target price; it is that the market is being told Brookfield can keep compounding fee-bearing capital without needing to fully re-rate the multiple. That matters because, in alternatives, scale begets fundraising momentum: if the platform can keep stacking flagship inflows while buying back stock, the equity behaves less like a cyclical asset manager and more like a capital-efficient compounder. The under-levered balance sheet comment also implies room for incremental capital returns or strategic deployment if fund raising stays strong.

Second-order beneficiaries sit outside the obvious peer set. A stronger Brookfield fundraising machine tends to pull more capital toward private credit, infrastructure, and real asset sleeves, which can pressure smaller managers that rely on the same LP wallets and distribution channels. It also reinforces the “winner-take-more” dynamic among large diversified alternative platforms, where a few firms can absorb volatility and still harvest management fees, while mid-tier peers face higher marginal fundraising costs.

The main risk is not near-term earnings; it is a three- to twelve-month normalization risk if the fundraising cadence slips or deployment gets harder in a choppier macro tape. If investors start discounting the quality of the capital raise mix — e.g., more bridge capital, longer fundraising cycles, or lower expected carry conversion — the valuation ceiling could compress back toward the peer multiple even if reported operating metrics stay solid. In that case, buybacks and the dividend only provide a floor, not a re-rating catalyst.

The contrarian point is that the current setup may already be pricing Brookfield as a pure quality compounder, while the real upside comes from operating leverage in fee-related earnings rather than headline AUM growth. If that operating leverage is underestimated, the stock can outperform even in a slower fundraising environment; if it is overestimated, the multiple expansion case stalls quickly. In other words, the debate is less about whether Brookfield is good, and more about whether the market is underappreciating how much incremental capital raise translates into distributable earnings per share over the next 12-18 months.

Key Decisions for Investors

• Go long BAM on pullbacks toward the low-$50s over a 1-3 month horizon; upside is driven by fee-related earnings leverage and buyback support, with downside limited by capital-return yield and balance-sheet flexibility.
• Pair trade: long BAM / short BX for 3-6 months if the market starts rewarding operating leverage over pure scale; BAM has more room for multiple catch-up if fundraising remains above expectations.
• Buy a 6-12 month BAM call spread financed partly by selling upside into the revised target zone; risk/reward is attractive if the market re-rates the stock on 2026 fundraising visibility.
• If BAM rallies quickly into the mid-$60s before evidence of the next fundraising cycle, trim 25-50%: the re-rating likely needs continued proof of capital formation, not just guidance commentary.
• Use BAM as a relative long versus smaller listed alternatives managers with less diversified fundraising streams; the trade benefits from industry concentration and could outperform over the next two reporting cycles.